Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224584
Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-Kidney Transplantation
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background. Pancreas graft status in simultaneous pancreas-kidney transplant (SPKTx) is currently assessed by nonspecific biochemical markers, typically mylase or lipase. Identifying a noninvasive biomarker with good sensitivity in detecting early pancreas graft rejection could improve SPKTx management. Methods. Here, we developed a pilot study to explore donor-derived cell-free DNA (dd-cfDNA) performance in predicting biopsy-proven acute rejection (P-BPAR) of the pancreas graft in a cohort of 36 SPKTx recipients with biopsy-matched plasma samples. dd-cfDNA was measured using the Prospera test (Natera, Inc.) and reported both as a fraction of the total cfDNA (fraction; %) and as concentration in the recipient’s plasma (quantity; copies/mL). Results. In the absence of P-BPAR, dd-cfDNA was significantly higher in samples collected within the first 45 d after SPKTx compared with those measured afterward median, 1.00% versus 0.30%; median, 128.2 versus 35.3 cp/mL, respectively with both; P=0.001). In samples obtained beyond day 45, P-BPAR samples presented a significantly higher dd-cfDNA fraction (0.83 versus 0.30%; P=0.006) and quantity (81.3 versus 35.3 cp/mL; P=0.001) than stable samples. Incorporating dd-cfDNA quantity along with dd-cfDNA fraction outperformed dd-cfDNA fraction alone to detect active rejection. Notably, when using a quantity cutoff of 70 cp/mL, dd-cfDNA detected P-BPAR with a sensitivity of 85.7% and a specificity of 93.7%, which was more accurate than current iomarkers (area under curve of 0.89 for dd-cfDNA (cp/ml) compared with 0.74 of lipase and 0.46 for amylase). Conclusions. dd-cfDNA measurement through a simple noninvasive blood test could be incorporated into clinical practice to help inform graft management in SPKTx patients.
Matèries (anglès)
Citació
Citació
VENTURA ABREU AGUIARÀ, Pedro, RAMÍREZ BAJO, María josé, ROVIRA JUÁREZ, Jordi, BAÑÓN MANEUS, Elisenda, HIERRO GARCÍA, Natalia, LAZO RODRÍGUEZ, Marta, CUATRECASAS FREIXAS, Miriam, GARCIA CRIADO, María ángeles, LIANG, Nathan, SWENERTON, Ryan k., COFÁN PUJOL, Federico, CUCCHIARI, David, ESFORZADO, Núria, MONTAGUD MARRAHI, Enrique, OPPENHEIMER SALINAS, Federico, PIÑEIRO, Gastón julio, REVUELTA VICENTE, Ignacio, TORREGROSA, Vicens, AHMED, Ebad, SOBOLEVA, Karina, KAUR, Navchetan, ZIMMERMANN, Bernhard g., AL HAJ BADDAR, Nour, DEMKO, Zachary p., ESCRIG, Cesar, TABRIZIANI, Hossein, GAUTHIER, Philippe, BILLINGS, Paul r., AMOR FERNÁNDEZ, Antonio jesús, FERRER FÁBREGA, Joana, CAMPISTOL PLANA, Josep m., DIEKMANN, Fritz. Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-Kidney Transplantation. _Transplantation_. 2022. Vol. 106, núm. 8, pàgs. 1690-1697. [consulta: 7 de gener de 2026]. ISSN: 0041-1337. [Disponible a: https://hdl.handle.net/2445/224584]